At this year’s AAN annual meeting, investigators reported that among the neurodegenerative disorders associated with REM sleep behavior disorder (RBD), 94 percent were synucleinopathies, indicating, experts
say, that REM sleep behavior disorder is a highly
significant prognostic indicator of future neurodegenerative disease. The findings “argue that part of the selective vulnerability
involved with Lewy body disease and with MSA likely involves REM sleep circuitry,” study leader Bradley Boeve, MD, chair of behavioral neurology at the Mayo Clinic in Rochester, MN, told attendees of the plenary at the AAN annual meeting. In a video interview, Neurology Today
Editor-in-chief Steven P. Ringel, MD, and Associate Editor Robert G. Holloway, MD, discuss the implications of the study and what to tell patients and their families once REM sleep behavior disorder is diagnosed.